Agricultural Health Study Follow-up
NCT01399411
Asthma, Autoimmune Diseases
Iowa City, Illinois, United States
View Trial DetailsNCT Number: NCT03990402
The main aim of the study is to identify altogether 3000 children aged between 12 and 16 years old with asthma symptoms in six sub-Saharan African countries. The study furthermore aims to assess their asthma control, current treatment, knowledge of and attitudes to asthma, as well as the barriers to achieving good asthma control.
Looking for future studies?
Notify Me12 year–14 year
All sexes
Observational
Kwame Nkrumah University of Science & Technology (KNUST), Kumasi, Ashanti Region, Ghana
Asthma prevalence in young people has been rising in several African countries during the last decade, reaching between 10% and 20% in Central Africa, and up to 20% in South Africa. In addition, asthma related mortality in many African countries is high. South Africa has the third highest asthma related mortality rate in the world. Yet to date, a lack of asthma research and research infrastructure means that we do not have the evidence to either inform advocacy or to develop interventions that improve asthma outcomes.
This study aims to collect data about asthma prevalence and to identify existing barriers to effective asthma management of young people in 6 sub-Saharan countries: Malawi, South Africa, Zimbabwe, Uganda, Ghana, and Nigeria. Each of these countries identifies 500 young people with asthma between 12 and 16 years of age through a screening questionnaire in schools. These 3000 young people with asthma symptoms fill in a survey about asthma, including questions around asthma control, current treatment and access to care, asthma knowledge, asthma attitudes, smoking and environmental influences. Some of the participants also discuss asthma related topics in focus groups. A subset of the participants furthermore do Spirometry and FeNO testing. In addition to the data collection, the study develops and tests options for an intervention aimed at improving asthma control, including the adaption of a United Kingdom - based theater play about asthma awareness. The development of WiFi infrastructure and IT solutions is promoted by the study, where appropriate.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 12 months
Percentage of children with asthma or asthma symptoms, based on GAN (Global Asthma Network) screening tool.
Time frame: 1 year
set of questions about asthma knowledge, maximum knowledge score is 13, minimum knowledge score is 0, total range is 13. Higher values represent better knowledge.
Time frame: 1 year
Each of the 9 items in the Brief Illness Perception Questionnaire has a minimum score of 0 and a maximum score of 10.
The consequences score is the response to item 1. The timeline score is the response to item 2. The personal control scores is the response to item 3. The treatment control score is the response to item 4. The identity score is the response to item 5. The coherence score is the response to item 7. The emotional representation is the response to item 8. Illness concern is measured by item 6. Item 9 is the causal item.
Overall score which represents the degree to which the illness is perceived as threatening or benign. To compute that score, reverse score items 3, 4, and 7 and add these to items 1, 2, 5, 6, and 8. A higher score reflects a more threatening view of the illness. The overall score has a minimum score of 0 and a maximum score is 80.
Time frame: 4 weeks
using validated ACT - Asthma Control Test (license by GlaxoSmithKlyne). The minimum score is 5 (poor control of asthma), the maximum score is 25 (complete control of asthma). An ACT score >19 indicates well-controlled asthma
Time frame: 1 year
questions related to the environment of young people with asthma symptoms, reported using descriptive statistics, and percentages
Time frame: 1 year
set of questions related to access to medical care, reported using descriptive statistics, and percentages
Time frame: 1 year
set of questions about current medication, reported using descriptive statistics, and percentages
Time frame: 1 year
set of questions asking about adherence to medication, reported as descriptive statistics and percentages, as well as free text comments.
Time frame: 4 weeks
questions asking about asthma-related time off school, reported as descriptive statistics and percentages
Time frame: 1 year
questions assessing active and passive smoking, reported as descriptive statistics and percentages
Time frame: up to 1 day
FeNO measurements - exhaled Nitric Oxide
Time frame: up to 1 day
FEV1, in liter, and in liter predicted
Time frame: 4 weeks
GINA questionnaire (Global INitiative for Asthma) using four questions, assessing control of asthma symptoms. Outcome is 'well controlled' if none of the four questions is answered 'Yes', 'partly controlled' if one or two of the four questions is answered 'Yes', uncontrolled, if three or four of the four questions is answered 'Yes'.
Time frame: up to 1 day
FVC, in liter, and in liter predicted
Time frame: up to 1 day
Ratio of FEV1 to FVC
Time frame: up to 1 day
FEF25-75 as percentage
Queen Mary University of London
Other
GHR (Global Health Research) Project:17/63/38 - NIHR (National Institute for Health Research) Global Health Research Group on Improving Asthma Outcomes in African Children at Queen Mary University of London
Acronym: ACACIA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01399411
Asthma, Autoimmune Diseases
Iowa City, Illinois, United States
View Trial DetailsNCT01678222
Allergic Inflammation, Asthma
Research Triangle Park, North Carolina, United States
View Trial DetailsNCT00001888
Asthma, Bronchial Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT07746570
Asthma, Bronchial Diseases
Erzincan, Merkez, Turkey (Türkiye)
View Trial Details